22nd Century Group, Inc., headquartered in Williamsville, New York, specializes in agricultural biotechnology focusing on tobacco harm reduction and plant science innovations using genetic engineering and molecular breeding. The company, which went public in 2006, operates primarily in the tobacco industry, producing reduced nicotine cigarettes and providing contract manufacturing for other brands.
XXII has been in the news recently: XXII reported a 10% revenue increase last quarter, leading to a doubled stock price. Additionally, they have partnered with Nico-Tech Korea, Inc. to launch VLN® reduced nicotine content cigarettes in South Korea's tobacco market.
📡️ Consumer Staples
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
